News

10x Genomics Unveils Affordable Solutions for Single Cell Analysis

10x Genomics Unveils Affordable Solutions for Single Cell Analysis

Innovations in Single Cell Analysis by 10x Genomics

At the recent Human Cell Atlas General Meeting, 10x Genomics, Inc. (NASDAQ: TXG) unveiled groundbreaking plans that promise to revolutionize single cell analysis. This exciting announcement is a significant step towards making advanced single cell technology accessible to researchers across the globe.

Affordable Mega-Scale Single Cell Solutions

During a presentation at the meeting, 10x Genomics revealed its ambitious strategy to provide single cell analysis at a remarkable price of one cent per cell. This initiative demonstrates the company's commitment to lowering barriers for researchers looking to utilize single cell technology. With new products projected to launch in the near future, 10x Genomics is poised to offer services that enable analysis of 2.5 million cells in a single run, and up to 5 million cells per kit. These features position their solutions as the most economically viable option available for high-throughput applications such as CRISPR screens and cell atlassing.

The Importance of Cost-Effective Research Tools

Michael Schnall-Levin, Founding Scientist and CTO at 10x Genomics, highlighted the significance of having affordable options for both novice and seasoned researchers. He stated, "Price is an important consideration, both for new researchers embarking on their first single cell experiment and for our current customers wanting to analyze more cells or conduct experiments more regularly." Their continued focus on providing high-performance and cost-effective solutions will drive broader adoption across various research fields.

New Launches to Expand Accessibility

10x Genomics is not only focused on mega-scale applications but is also committed to offering new products that will enhance access to single cell analysis in numerous applications. Researchers will have the opportunity to conduct single cell experiments for an estimated cost of around $560 per sample, thus promoting widespread use across different stages of research.

Prior Innovations Leading to Current Offerings

Earlier this year, 10x Genomics introduced several innovative products designed to make single cell analysis more affordable. These advancements in technology and strategic launches are part of the company’s broader mission to democratize single cell analysis. Noteworthy products include the Chromium GEM-X Technology, which significantly improves sensitivity and scalability and reduces costs dramatically.

Highlights of New Instruments

Another significant launch was the Chromium Xo, notable for its affordability among single cell instruments at a U.S. list price of $25,000. Schnall-Levin expressed confidence in these new products stating that they would reinforce 10x's leadership in both performance and cost, ensuring researchers do not have to compromise on quality due to budget constraints.

About 10x Genomics

10x Genomics is a pioneering life science technology company dedicated to providing integrated solutions that advance biological research. Their comprehensive suite of instruments, consumables, and software enables researchers to explore the complexity of biological systems like never before. With applications in oncology, immunology, and neuroscience, their technologies are essential for ground-breaking discoveries reshaping our understanding of health and disease.

Frequently Asked Questions

What is the significance of the recent announcement by 10x Genomics?

The announcement marks a major step in making single cell analysis more accessible and affordable for researchers, paving the way for wider adoption of this technology.

How will the new products affect single cell research?

The new products are designed to provide high-performance analysis at a significantly lower cost, allowing for more extensive data collection and experimentation at all levels of research.

What are the key features of the Chromium GEM-X Technology?

This technology promises increased sensitivity and capture efficiency, along with an improved cost per cell, making it a game-changer for researchers.

What benefits does the Chromium Xo offer?

Chromium Xo is the most affordable single cell instrument on the market, providing high-quality data with superior reliability at a competitive price point.

How does 10x Genomics plan to support researchers?

By continually lowering costs and enhancing product offerings, 10x Genomics aims to empower researchers to explore and understand biological systems in greater detail.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 0

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 3

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 3

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 3

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into bluebird bio, Inc.’s Acquisition Proposal

Updated Category News Views 167

Understanding the Investigation into bluebird bio, Inc. Recent developments have captured the attention of shareholders and the financial community regarding bluebird bio, Inc. (NASDAQ: BLUE). Rowley Law PLLC has initiated an investigation exploring possible violations of securities law associated with the company’s proposed acquisition. This acquisition is a joint...

Continue Reading
Unwind in Paradise: The Seminyak Beach Resort's Escape

Updated Category News Views 105

Experience Tranquility at The Seminyak Beach Resort & Spa The Seminyak Beach Resort & Spa invites travelers everywhere to immerse themselves in the serene beauty of Bali with its new Seaside Escape package. This luxurious beachfront haven is celebrated for its genuine Balinese artistry and exceptional service, perfectly catering to those who seek a unique blend of...

Continue Reading
Lyte Fiber Launches Advanced Network to Enhance Connectivity

Updated Category News Views 468

Lyte Fiber Unveils Innovative Fiber Network Project Lyte Fiber, LLC is making significant strides in enhancing digital connectivity by initiating construction on its state-of-the-art multi-gigabit fiber network. This investment, amounting to over $11 million, aims to transform the digital landscape for homes and businesses. The company envisions an upgraded digital...

Continue Reading
ONE Gas Boosts Commercial Paper Program for Financial Flexibility

Updated Category News Views 67

ONE Gas Expands Its Commercial Paper Program ONE Gas, Inc. (NYSE: OGS), a prominent natural gas distribution company, has announced a significant increase in the limit of its commercial paper program. This update, disclosed through a recent SEC filing, raises the program's ceiling from $1.275 billion to $1.35 billion, reflecting the company's proactive approach in...

Continue Reading
Sogeclair's Voting Rights Update for Stakeholders in 2025

Updated Category News Views 133

Sogeclair's Insights on Voting Rights and Share Capital SOGECLAIR As a prominent business corporation with a capital of 3,204,901 Euros, Sogeclair is dedicated to maintaining transparency in its operations. The company is headquartered at 7 Avenue Albert Durand, BLAGNAC (France). If you need to reach out, the contact number is +33 (0)5.61.71.71.71 and more about the...

Continue Reading